(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck small research deals.